Adverum Biotechnologies Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume540,782 shs
Average Volume1.94 million shs
Market Capitalization$220.78 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Adverum Biotechnologies logo

About Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.38 out of 5 stars

Medical Sector

182nd out of 1,352 stocks

Biological Products, Except Diagnostic Industry

24th out of 193 stocks

Analyst Opinion: 4.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

Is Adverum Biotechnologies a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 10 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Adverum Biotechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares.
View analyst ratings for Adverum Biotechnologies
or view top-rated stocks.

What stocks does MarketBeat like better than Adverum Biotechnologies?

Wall Street analysts have given Adverum Biotechnologies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adverum Biotechnologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Adverum Biotechnologies

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings results on Wednesday, August, 4th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.07.
View Adverum Biotechnologies' earnings history

How has Adverum Biotechnologies' stock been impacted by COVID-19?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADVM stock has decreased by 75.7% and is now trading at $2.25.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ADVM?

10 equities research analysts have issued 12 month target prices for Adverum Biotechnologies' shares. Their forecasts range from $2.00 to $13.00. On average, they anticipate Adverum Biotechnologies' share price to reach $6.43 in the next year. This suggests a possible upside of 185.7% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Laurent Fischer, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Peter Soparkar, Chief Operating Officer
  • Christopher J. DeRespino, Chief Financial, Accounting & Business Officer
  • Angela Thedinga, Chief Technology Officer
  • Brigit Riley, Chief Scientific Officer

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (9.76%), BlackRock Inc. (8.14%), RTW Investments LP (7.50%), Avoro Capital Advisors LLC (7.08%), Vanguard Group Inc. (4.43%) and JPMorgan Chase & Co. (2.39%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Laurent Fischer, Leone D Patterson, Mehdi Gasmi, Patrick Machado and Peter Soparkar.
View institutional ownership trends for Adverum Biotechnologies

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Goldman Sachs Group Inc., Price T Rowe Associates Inc. MD, UBS Asset Management Americas Inc., WS Management Lllp, Vanguard Group Inc., Allianz Asset Management GmbH, and Rafferty Asset Management LLC.
View insider buying and selling activity for Adverum Biotechnologies
or view top insider-selling stocks.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Renaissance Technologies LLC, Deutsche Bank AG, Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, and Morgan Stanley. Company insiders that have bought Adverum Biotechnologies stock in the last two years include James Paul Scopa, Laurent Fischer, Patrick Machado, and Peter Soparkar.
View insider buying and selling activity for Adverum Biotechnologies
or or view top insider-buying stocks.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $2.25.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies has a market capitalization of $220.78 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-117,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

Adverum Biotechnologies employs 167 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is

Where are Adverum Biotechnologies' headquarters?

Adverum Biotechnologies is headquartered at 800 Saginaw Drive, Redwood City CA, 94063.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at (650) 656-9323 or via email at [email protected].

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.